By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina today announced it has been selected as a preferred service provider for Cancer Research UK.

As a result, Illumina will provide a range of services, starting with whole genome sequencing, to support the International Cancer Genome Consortium, which aims to develop a comprehensive description of genomic, transcriptomic, and epigenomic changes in 50 different tumor types and/or subtypes of clinical and societal importance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.